EZ BAA Deadline: Novel Coronavirus Rapid Diagnostic
Under this EZ BAA, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, will review concise abstract submissions for development funding of 2019-nCoV molecular diagnostics. The diagnostics must utilize platforms already cleared by the U.S. Food and Drug Administration, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.
This area of interest will be open for abstract submissions until 30 April 2020, unless otherwise extended.
Learn more about this EZ BAA opportunity in Funding News.
Global Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.